20:59 , Aug 16, 2019 |  BioCentury  |  Emerging Company Profile

A-Alpha retools yeast sex for high throughput drug discovery

A-Alpha is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles, small...
22:08 , Aug 13, 2019 |  BC Extra  |  Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

Eli Lilly said Taltz was superior to J&J's Tremfya in treating psoriasis at 12 weeks in the Phase IV IXORA-R trial, but the data may not move the needle on physicians’ prescribing habits. The data...
00:33 , Aug 10, 2019 |  BC Extra  |  Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

Nektar tumbles on bempegaldesleukin revelation   Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial...
20:36 , Aug 7, 2019 |  BC Extra  |  Financial News

Glycomine looks toward clinic with Novo-led $33M round

Glycomine raised a tranched $33 million series B round to take its lead rare congenital disease therapy into the clinic. Novo Holdings A/S led the round. Additional new investors Asahi Kasei Pharma Corp. and Mission...
11:04 , Aug 6, 2019 |  BC Extra  |  Financial News

IPD spinout Neoleukin merges with Aquinox for NASDAQ listing

Neoleukin thinks its merger with Aquinox announced Tuesday will enable the de novo protein design newco to submit an IND for its IL-2 mimetic and announce additional preclinical programs by the end of 2020. The...
23:42 , Aug 2, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 14 profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket in New York; during market hours in Tel Aviv Company Date Pre/post mkt 2Q19 EPS est...
01:41 , Aug 2, 2019 |  BC Innovations  |  Translation in Brief

A charged system for insulin delivery

A charge-based glucose-binding switch is the latest technology aimed at enabling automatic insulin control. With proof-of-concept experiments in mice and minipigs, the system could rival preclinical technologies picked up by Eli Lilly, Merck and Novo...
20:29 , Jul 31, 2019 |  BC Extra  |  Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
00:48 , Jul 26, 2019 |  BC Innovations  |  Product Development

Institute for Protein Design's de novo revolution

Seattle's Institute for Protein Design is growing an army of spinouts that build proteins from the ground up. With applications ranging from multivalent vaccines and synthetic cytokines to precision cell therapies, these companies could put...
00:28 , Jul 25, 2019 |  BC Extra  |  Financial News

July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more

Seattle Genetics raises $500M follow-on  Seattle Genetics Inc. (NASDAQ:SGEN) raised $500 million late Tuesday through the sale of 7.1 million shares at $70. The price is an 8% discount to the company's close of $75.95...